The Hidden Cost of Rapid Weight Loss: How GLP-1 Drugs May Be Weakening Bones and Tearing Tendons

As millions of Americans shed pounds on Ozempic and Wegovy, a growing body of research reveals that the skeleton and soft tissues may be paying the price.

The rise of GLP-1 receptor agonist drugs has been one of the most consequential developments in modern medicine. Semaglutide, sold under the brand names Ozempic and Wegovy, along with tirzepatide (Mounjaro and Zepbound), have transformed the treatment of obesity and Type 2 diabetes, helping patients lose 15-25% of their body weight. Prescriptions for GLP-1 drugs to treat overweight or obesity rose 587% from 2019 to 2024 [1], and roughly one in eight American adults now reports currently taking one [2].

But as these medications have gone from niche diabetes treatments to cultural phenomena — with a global market projected to reach $122.3 billion by 2030 [3] — a troubling pattern has begun to emerge in orthopedic clinics and research labs across the country. Multiple new studies suggest that GLP-1 drugs are associated with increased risks of osteoporosis, bone fractures, and tendon ruptures, raising urgent questions about what happens to the musculoskeletal system when the body loses weight this rapidly.

The Orthopedic Surgeon Who Noticed a Pattern

Dr. John Horneff, an associate professor of orthopedic surgery at the University of Pennsylvania, began investigating the issue after noticing something unusual in his practice: patients on GLP-1 medications were showing up with serious tendon tears following what should have been minor injuries [4].

His curiosity led to a large-scale analysis of more than 146,000 adults with obesity and Type 2 diabetes, examining five years of medical records. The findings, presented on March 2, 2026 at the American Academy of Orthopaedic Surgeons (AAOS) annual meeting, paint a concerning picture [4]:

• Osteoporosis: About 4% of GLP-1 users developed osteoporosis, compared with 3.1% of nonusers — an approximately 30% increased risk.
• Osteomalacia (bone softening): This rare condition occurred roughly twice as often among GLP-1 users.
• Gout: Rates were 7.4% for GLP-1 users versus 6.6% for nonusers — a 12% increased risk.
• Bone mineral density disorders: The risk of having some form of bone mineral density problem nearly doubled at the five-year mark among GLP-1 users.

Importantly, the study has not yet been peer-reviewed. But it adds to a growing and increasingly consistent body of evidence.

Tendons Under Strain

A separate analysis, also presented at the AAOS meeting and reported by Medscape, focused specifically on tendon health in patients with obesity using GLP-1 receptor agonists [5]. Over five years, GLP-1 use was associated with significantly higher risks of major tendon ruptures:

• Rotator cuff rupture: 2.4% in GLP-1 users vs. 1.5% in controls (hazard ratio 1.55)
• Achilles tendon rupture: 0.3% vs. 0.2% (hazard ratio 1.49)
• Pectoralis major rupture: 0.8% vs. 0.5% (hazard ratio 1.46)

These are not trivial injuries. A rotator cuff tear can mean months of rehabilitation or surgery. An Achilles rupture can end an athletic career. And the hazard ratios — ranging from 1.46 to 1.55 — indicate meaningfully elevated risk, not statistical noise.

Source: AAOS 2026 / Medscape

Data as of Mar 8, 2026CSV

A Second Study Confirms the Fracture Signal

In February 2026, a study published in the peer-reviewed Journal of Clinical Endocrinology & Metabolism examined 46,177 older adults with Type 2 diabetes and found that those who started GLP-1 receptor agonists had an 11% higher risk of fragility fractures compared to patients on other diabetes medications (hazard ratio 1.11; 95% CI, 1.01–1.21) [6].

During a median follow-up of nearly three years, 8.8% of the cohort experienced a fragility fracture. Lead author Dr. Michal Kasher Meron, an endocrinologist at Meir Medical Center in Israel, cautioned that while the relative increase may sound modest, "it carries weight for an at-risk population" [6].

Tirzepatide may pose even greater skeletal risk. A separate retrospective study using the TriNetX database found that tirzepatide was associated with a 44% higher risk of osteoporosis or fragility fractures compared to other GLP-1 receptor agonists (hazard ratio 1.44) [7].

Why Weight Loss Weakens the Skeleton

The mechanisms connecting GLP-1-driven weight loss to bone and tendon problems are multifaceted, and researchers are still working to untangle direct drug effects from the consequences of rapid weight loss itself.

Reduced mechanical loading. The skeleton adapts to the forces placed upon it. When a person loses 15-25% of their body weight in a matter of months, the bones that have been calibrated to support a heavier frame suddenly bear significantly less load. Dr. Clifford Rosen, a professor of medicine at Tufts University, has compared this to the bone density losses astronauts experience in zero gravity — the skeleton, no longer under its accustomed stress, begins to thin [4].

A 10% reduction in body weight has been associated with a 2.2% decrease in lumbar and total hip bone mineral density [8]. With GLP-1 drugs routinely producing weight loss of 15-20%, the cumulative skeletal impact may be substantial.

Lean mass loss. Up to 40% of the weight lost on semaglutide — and up to 25% on tirzepatide — comes from lean body mass rather than fat [9]. While some researchers argue this proportion is comparable to other weight-loss interventions, the sheer magnitude of weight loss with GLP-1 drugs means the absolute amount of muscle lost can be significant. Less muscle mass means less structural support for tendons and joints, potentially explaining the elevated rupture rates.

Nutritional deficiencies. GLP-1 drugs work partly by suppressing appetite, and many patients eat substantially less while on them. "People are taking these medications, and obviously there's a tremendous amount of upside," Horneff told NBC News. "But with that, they start to decrease their intake of food and nutrients" [4]. Inadequate calcium, vitamin D, and protein intake can directly compromise both bone density and tendon integrity.

Metabolic shifts. Rapid weight loss triggers elevated uric acid levels — a byproduct of tissue breakdown — which helps explain the 12% increase in gout risk observed in GLP-1 users [4]. There is also emerging evidence that bone marrow adiposity, hormonal changes, and disruptions to energy metabolism during rapid weight loss contribute to skeletal fragility [8].

The Complexity: Some Evidence Points the Other Way

The picture is not entirely one-directional. A systematic review of 25 studies found that GLP-1 receptor agonists were associated with significantly improved bone mineral density at the lumbar spine and femoral neck in Type 2 diabetes patients over age 55 [9]. Some meta-analyses have found no increased overall fracture risk with GLP-1 drugs. And GLP-1 receptor agonists appear to have genuine anti-inflammatory properties in joints — reducing key inflammatory markers like TNF-alpha, IL-6, and IL-1beta — suggesting potential benefits for conditions like osteoarthritis [9].

One large cohort study even found reduced cartilage loss and lower knee surgery incidence among GLP-1 users [9]. And patients on these drugs who underwent joint replacement surgery showed lower rates of periprosthetic joint infections, sepsis, and 90-day readmissions [9].

"This does not need to be an either/or," said Dr. Christopher McGowan, a gastroenterologist who directs a weight loss clinic in North Carolina. "The takeaway isn't fear. It's refinement" [4].

A Market Outpacing Its Safety Data

The tension between the enormous benefits of GLP-1 drugs and their emerging musculoskeletal risks plays out against a backdrop of staggering commercial growth. The global GLP-1 market was valued at $45.3 billion in 2024 and is projected to reach $122.3 billion by 2030, growing at 18% annually [3]. More than 60 companies are developing GLP-1 drugs, with over 135 candidates in clinical trials [3].

Source: GlobeNewsWire / JPMorgan / KFF

Data as of Mar 8, 2026CSV

An estimated 10 million Americans were on GLP-1 treatment in 2025, a figure projected to reach 25 million by 2030 [3]. The user base is broad: a 2025 KFF poll found that women (15%) are more likely than men (9%) to currently be taking GLP-1 drugs, with the highest usage among adults ages 50-64 (22%) [2] — precisely the demographic most vulnerable to bone density loss and tendon degeneration.

The FDA's existing label for semaglutide already notes a potential increased risk of bone fractures in older adults and women [10]. But critics argue that the pace of real-world adoption has far outstripped the availability of long-term safety data, particularly regarding musculoskeletal outcomes.

What Patients and Doctors Should Do Now

Researchers and clinicians interviewed for this story consistently emphasized that the findings do not warrant abandoning GLP-1 therapy — the cardiovascular, metabolic, and quality-of-life benefits are well-established. Instead, they call for a more comprehensive approach to managing patients on these drugs.

Exercise is non-negotiable. A randomized clinical trial published in JAMA Network Open found that participants who combined GLP-1 receptor agonist treatment (liraglutide) with structured exercise did not experience bone density loss, unlike those who took the medication without exercising [11]. Heavy resistance training and weight-bearing exercise are particularly protective. Dr. Susan Spratt, an endocrinologist and senior medical director at Duke Health, emphasized that exercise should be treated as a co-prescription alongside GLP-1 drugs [4].

Nutritional monitoring is essential. Clinicians should proactively screen for calcium, vitamin D, and protein intake deficiencies in GLP-1 patients. Preoperative nutritional surveillance — including albumin and total lymphocyte count — is recommended for GLP-1 users who require surgery [9].

Baseline and follow-up bone density scans. Experts recommend obtaining a DXA (dual-energy X-ray absorptiometry) scan before starting GLP-1 therapy and repeating it at regular intervals, particularly for older adults, postmenopausal women, and patients with existing bone density concerns [12].

Perioperative precautions. Because GLP-1 drugs cause delayed gastric emptying, current anesthesia guidelines recommend discontinuing them 1-4 weeks before scheduled surgery to reduce aspiration risk [9].

The Bigger Picture

The GLP-1 revolution is not slowing down. Oral formulations are in advanced development. Medicare recently began covering these drugs for obesity. Prices are falling. The number of Americans on GLP-1 therapy will almost certainly continue to climb.

That makes the emerging musculoskeletal data not a reason for alarm, but a call for vigilance. The history of medicine is full of breakthrough therapies whose full risk profiles only became clear after millions of patients had used them. The key question is whether the healthcare system can adapt quickly enough — implementing routine bone health monitoring, prescribing exercise alongside medication, and conducting the long-term studies needed to fully understand the skeletal cost of rapid pharmacological weight loss.

"We're not saying don't take these drugs," Horneff told reporters at the AAOS meeting. "We're saying, if you do, pay attention to the rest of your body too" [4].

The bones are listening — even when the scale is celebrating.